Literature DB >> 2268985

Therapeutic drug monitoring of phenytoin. Rationale and current status.

M Levine1, T Chang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2268985     DOI： 10.2165/00003088-199019050-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  113 in total

1.  Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.

Authors:  G J Johnson; C J Kilpatrick; R W Bury; R O Fullinfaw; R F Moulds
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

2.  Clinical utility of a Bayesian dosing program for phenytoin.

Authors:  M D Privitera; R W Homan; T M Ludden; C C Peck; M R Vasko
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

3.  One drug (phenytoin) in the treatment of epilepsy.

Authors:  E H Reynolds; D Chadwick; A W Galbraith
Journal:  Lancet       Date:  1976-05-01       Impact factor: 79.321

Review 4.  Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications.

Authors:  P J Neuvonen
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

5.  A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy.

Authors:  W Fröscher; M Eichelbaum; R Gugler; G Hildenbrand; H Penin
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

6.  Accuracy of three methods for predicting concentrations of free phenytoin.

Authors:  D E Beck; J A Farringer; W R Ravis; C A Robinson
Journal:  Clin Pharm       Date:  1987-11

7.  Phenytoin dosage requirements and pharmacokinetic variables.

Authors:  J W Taylor; M J Murphy; M J Berg; P J Perry; L W Lyon; T M Ludden
Journal:  Clin Pharm       Date:  1983 May-Jun

8.  Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.

Authors:  C Knott; A Hamshaw-Thomas; F Reynolds
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-02

9.  Predictability of phenytoin serum levels by nomograms and clinicians.

Authors:  S Vozeh; A Koelz; E Martin; H Magun; G Scollo-Lavizzari; F Follath
Journal:  Eur Neurol       Date:  1980       Impact factor: 1.710

10.  Discontinuation of antiepileptic therapy: a prospective study in children.

Authors:  P A Bouma; A C Peters; R J Arts; T Stijnen; J Van Rossum
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-12       Impact factor: 10.154
View more
  12 in total

Review 1.  Therapeutic drug monitoring and patient outcome. A review of the issues.

Authors:  A L Tonkin; F Bochner
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

3.  Protein binding predictions in infants.

Authors:  Patrick J McNamara; Jane Alcorn
Journal:  AAPS PharmSci       Date:  2002

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

5.  Estimation of Free Phenytoin Concentration in Critically Ill Patients with Hypoalbuminemia: Direct-measurement vs Traditional Equations.

Authors:  Premila M Wilfred; Sumith Mathew; Binila Chacko; Ratna Prabha; Binu Susan Mathew
Journal:  Indian J Crit Care Med       Date:  2022-06

Review 6.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

7.  Diphenytoin, riluzole and lidocaine: three sodium channel blockers, with different mechanisms of action, decrease hippocampal epileptiform activity.

Authors:  Lihong Diao; Jennifer L Hellier; Jessica Uskert-Newsom; Philip A Williams; Kevin J Staley; Audrey S Yee
Journal:  Neuropharmacology       Date:  2013-05-21       Impact factor: 5.250

Review 8.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 9.  Selected pharmacokinetic issues of the use of antiepileptic drugs and parenteral nutrition in critically ill patients.

Authors:  Muhannad R M Salih; Mohd Baidi Bahari; Arwa Y Abd
Journal:  Nutr J       Date:  2010-12-31       Impact factor: 3.271

10.  Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients.

Authors:  Ji-Man Hong; Young-Chul Choi; Won-Joo Kim
Journal:  Yonsei Med J       Date:  2009-08-19       Impact factor: 2.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.